Zimmer Biomet Holdings, Inc.'s Stock Analysis

Zimmer Biomet Annual Meeting Results and Shareholder Votes

Zimmer Biomet Holdings held its annual meeting of shareholders on May 22, 2026, where shareholders elected ten directors for one-year terms ending at the 2027 annual meeting. Additionally, the shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 and approved the advisory compensation of the Company’s named executive officers as disclosed in the proxy statement.

In contrast, a shareholder proposal for an Independent Board Chairman was rejected. The outcomes of these votes may influence investor sentiment and perceptions of corporate governance at Zimmer Biomet.

May 27, 2026 17:30:16

Zimmer Biomet Plans $1 Billion Share Repurchase in 2026

Zimmer Biomet Holdings, Inc. announced its intention to repurchase up to $1 billion of its common stock during fiscal year 2026. This marks a $250 million increase from previous capital allocation assumptions and will be conducted under the existing $1.5 billion share repurchase authorization approved by the Board of Directors in February 2026. The company may execute these repurchases in the open market or through structured agreements with third parties, depending on various market conditions and capital availability.

The announcement reflects the company's commitment to returning capital to shareholders while maintaining its operational strategies. The timing and exact amount of share repurchases will be influenced by market conditions and the company's stock price, among other factors. This increase in share repurchase expectations may have implications for the company's stock price and investor sentiment moving forward.

May 12, 2026 06:30:17

Zimmer Biomet CFO Resignation and Interim Appointment Announced

Suketu Upadhyay, the Chief Financial Officer of Zimmer Biomet Holdings, will resign effective April 28, 2026, to pursue a new opportunity. His departure is not due to any disagreements regarding the company's financial matters. Paul Stellato, who currently serves as Vice President, Controller, and Chief Accounting Officer, will take over as the interim Chief Financial Officer while the company searches for a permanent replacement.

In his interim role, Stellato will maintain his responsibilities as Controller and Chief Accounting Officer. He will receive an annual base salary of $550,000, along with a target annual bonus opportunity of 70% of his base salary, prorated for the time he serves as interim CFO. Additionally, Stellato will receive equity awards valued at approximately $750,000 in restricted stock units and $100,000 in performance-based restricted stock units, which will vest over a period of three years and are subject to performance goals.

Apr 28, 2026 06:33:21

Zimmer Biomet Reports First Quarter 2026 Financial Results

Zimmer Biomet Holdings, Inc. announced its financial results for the first quarter of 2026, reporting net sales of $2.087 billion, which is a 9.3% increase compared to the same period last year. The company also reported diluted earnings per share of $1.22, marking a 34.1% increase, with adjusted diluted earnings per share rising to $2.09, a 15.5% increase. Operating cash flow was reported at $359.4 million, and free cash flow was $245.9 million for the quarter.

The company has completed $250 million in share repurchases and appointed Dr. Jonathan M. Vigdorchik as its Chief Science, Technology and Medical Affairs Officer. Zimmer Biomet has made significant advancements in its product offerings, including the launch of the G7®TM Acetabular System and the ROSA® Knee with OptimiZe. The company has also updated its full-year financial guidance, reflecting its confidence in ongoing strategic initiatives and market conditions.

Apr 28, 2026 06:30:16

Zimmer Biomet Reports Q4 and Full-Year 2025 Financial Results

Zimmer Biomet Holdings reported fourth quarter net sales of $2.244 billion, marking a 10.9% increase compared to the same period last year. The company also noted a full-year net sales increase of 7.2%, totaling $8.232 billion. However, diluted earnings per share (EPS) for the fourth quarter decreased by 41.7% to $0.70, while adjusted EPS rose by 4.8% to $2.42. For the full year, diluted EPS decreased by 19.9% to $3.55, but adjusted EPS increased by 2.5% to $8.20. The company generated $1.697 billion in operating cash flow and $1.172 billion in free cash flow for the year.

Additionally, Zimmer Biomet's Board of Directors approved a new stock repurchase program allowing for the buyback of up to $1.5 billion in common stock, effective immediately with no expiration date. The company also highlighted recent achievements, including the FDA clearance for its ROSA Knee system and various product launches. The company is transitioning to a more direct sales organization in the U.S., which may impact sales guidance for 2026 but is expected to drive long-term growth.

Feb 10, 2026 06:30:26

Mark Bezjak Resigns from Zimmer Biomet Holdings Effective January 2026

Mark Bezjak, a named executive officer at Zimmer Biomet Holdings, has announced his resignation from the company and all associated positions, effective January 16, 2026. He is leaving to pursue another business opportunity. It is noted that Mr. Bezjak had already ceased to be an executive officer as of July 1, 2025.

Jan 12, 2026 09:00:34

Zimmer Biomet Reports Third Quarter 2025 Financial Results

Zimmer Biomet Holdings reported net sales of $2.001 billion for the third quarter of 2025, marking a 9.7% increase compared to the same period last year. The growth was attributed to a 5.6% organic revenue increase in the U.S. market, driven by the adoption of new products. However, the company experienced challenges in Latin America and Emerging Markets in Europe, which negatively impacted overall performance. Diluted earnings per share for the quarter were $1.16, while adjusted earnings per share rose to $1.90, reflecting a 9.2% increase.

The company has maintained its revenue growth guidance for the full year of 2025, narrowing its projections for constant currency and organic constant currency revenue growth. Recent developments include the acquisition of Monogram Technologies, which enhances its orthopedic robotics portfolio, and the approval of its iodine-treated hip implant in Japan. These innovations are part of the company’s strategy to drive growth, although they also face potential risks associated with market dynamics and integration challenges.

Nov 05, 2025 06:30:25

Zimmer Biomet Completes Acquisition of Monogram Technologies

Zimmer Biomet Holdings, Inc. has completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company, as of October 7, 2025. The merger agreement allows Monogram's shareholders to receive cash for their shares, with common stock valued at $4.04 and preferred shares receiving varying amounts based on their class. Monogram will now operate as a wholly owned subsidiary of Zimmer Biomet, which aims to enhance its portfolio of robotic and navigation technologies in orthopedic procedures.

The acquisition is expected to expand Zimmer Biomet's capabilities in robotic-assisted surgeries, including the introduction of semi- and fully autonomous robotic technologies. Monogram’s products, including a CT-based robotic system for knee surgeries, are anticipated to be commercialized with Zimmer Biomet's implants by early 2027. The deal also includes contingent value rights for Monogram's shareholders, potentially providing additional cash based on future performance milestones through 2030.

Oct 07, 2025 16:10:58

Zimmer Biomet Issues CHF 600 Million in New Bonds

Zimmer Biomet Holdings has issued two series of senior unsecured debt securities totaling CHF 600 million. This includes CHF 210 million in 0.930% Bonds maturing in 2030 and CHF 390 million in 1.560% Bonds maturing in 2035. Interest on both bonds will be paid annually, starting September 4, 2026.

The bonds include provisions for additional payments to non-U.S. holders to cover taxes, and the company may redeem the bonds under certain conditions. Holders can require the company to repurchase their bonds in case of a Change of Control Triggering Event. The bonds are subject to customary events of default and other covenants in the bond purchase agreement.

Sep 04, 2025 16:15:40

Zimmer Biomet Reports Q2 2025 Financial Results and Guidance

Zimmer Biomet Holdings, Inc. reported net sales of $2.077 billion for the second quarter of 2025, marking a 7.0% increase from the same period last year. The company also reported diluted earnings per share of $0.77, with adjusted diluted earnings per share rising by 3.0% to $2.07. The company has updated its full-year 2025 revenue growth guidance to a range of 6.7% to 7.7% and adjusted earnings per share guidance to between $8.10 and $8.30.

In addition to its financial results, Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies, expanding its offerings in surgical robotics. The company has also entered a strategic partnership with Getinge to distribute operating room products to Ambulatory Surgery Center customers. Other highlights include the launch of a direct-to-patient campaign for its knee solutions and recognition as one of America’s Best Mid-Size Companies in 2025 by TIME.

Aug 07, 2025 06:30:12